The availability of licensed paediatric drugs is lagging behind those for adults, and there is a
lack of safe formulations in suitable doses that children are able and willing to take. As a …

Although pharmacological therapies are recommended as a key component in the treatment
of attention-deficit hyperactivity disorder, their use continues to prompt intense debate …

Importance Pharmacogenomic (PGx) testing provides preemptive pharmacotherapeutic
guidance regarding the lack of therapeutic benefit or adverse drug reactions of PGx targeted …

Aims Eight years ago, a paper‐based survey was administered during the World Pharma
2010 meeting, asking about the challenges of implementing pharmacogenetics (PGx) in …

Whole-genome sequencing and whole-exome sequencing have proven valuable for
diagnosing inherited diseases, particularly in children. However, usage of sequencing data …

Prescribers today find themselves in a much more difficult position than has even been the
case in the entire history of medicine. Not only do they have available to them more drugs to …

Pharmacokinetics varies widely between children. Many factors play an important role in this
variability, such as ontogeny, pharmacogenetics, gender, comorbidities, and drug-drug …

The efficacy of proton pump inhibitor (PPI) medications is highly dependent on plasma
concentrations, which varies considerably due to cytochrome P450 (CYP2C19) genetic …

For the past several years, the implementation of pharmacogenetic (PGx) testing has
become widespread in several centers and clinical practice settings. PGx testing may be …

The safety and efficacy of pharmacotherapy in children, particularly preterms, neonates and
infants, is limited by a paucity of good‐quality data from prospective clinical drug trials. A …